UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, United States
Case Report
MET Exon 14 Resistance in Non-Small Cell Lung Cancer Case Report
Author(s): Auster ME, Xu Q, Kowalski J and Kaur S*
Introduction: Molecular testing has become standard of care in the treatment of Non-Small Cell Lung Cancer (NSCLC). Active driver mutations will often guide therapies, especially in the advanced setting, in which resistance is a likely event. With increasing molecular testing results, it is unclear how to effectively prioritize them to structure each next line of treatment. Herein, we report on a case with a MET exon 14 skipping mutation who developed resistance after treatment with a type 1b targeted TKI.
Case report: Our patient presented as a 76-year-old Hispanic female with newly diagnosed stage IV NSCLC adenocarcinoma. She was found to have a MET exon 14 skipping mutation and was initiated on capmatenib in accordance with the geometry trial. She had a partial response with resolution of her symptoms for about 6 months .. View More»
DOI:
10.35248/2471-8556.25.11(1).004